Volunteers are the backbone of our charity and represent us in communities right across the UK. We have more than six times as many people volunteering ...

Patients with advanced non-small cell lung cancer who received telehealth palliative care visits experienced comparable quality of life as those patients ...

Imfinzi (durvalumab) when given as a consolidation treatment after chemoradiation significantly improved survival compared to a placebo (inactive drug) for ...

The addition of retroperitoneal lymphadenectomy (removal of the lymph nodes at the back of the abdomen) to cytoreductive surgery (removal of cancer from the ...

Patients with locally advanced, unresectable (not able to be surgically removed), stage 3 non–small cell lung cancer (NSCLC) with an EGFR mutation ...

Neoadjuvant (primary cancer treatment) Opdivo (nivolumab) plus Yervoy (ipilimumab) followed by therapeutic lymph node dissection (surgical removal of the ...

Enhertu (fam-trastuzumab deruxtecan-nxki; Enhertu) improved progression-free survival (PFS) over chemotherapy in pretreated patients with hormone receptor ...

Presurgical treatment with paclitaxel, Herceptin (trastuzumab) and Perjeta (pertuzumab) led to a clearance of circulating tumor DNA (ctDNA; cancer DNA ...

We’ve enlisted a few of our research experts to help guide you through some of the most important announcements at the world’s biggest cancer ...

Patients with relapsed/refractory multiple myeloma tended to live longer without their disease worsening (progression-free survival; PFS) when treated with ...

Perioperative chemotherapy (treatment around the time of surgery) with chemotherapies demonstrated survival benefits, compared with neoadjuvant ...

Rybrevant (amivantamab) plus Leclaza (lazertinib) led to promising outcomes in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) that ...